This compound inhibits HCC self-renewal and tumor initiation through suppression of gene (Oct4, KLF4, Nanog, and SOX2) and surface marker (CD133+/ALDH1+) expression of LCSCs (Figure 2A.)[125]. This evidence concerns the gene NANOG and hepatocellular carcinoma.